ORCID as entered in ROS

Select Publications
2023, 'Attenuated PBMC Cytokine Production in Hidradenitis Suppurativa May Be Indicative of Cellular Exhaustion, Providing Novel Biomarkers, and Future Therapeutic Potential', Journal of Investigative Dermatology, 143, pp. 2334 - 2337, http://dx.doi.org/10.1016/j.jid.2023.05.020
,2023, 'Resident cutaneous memory T cells: a clinical review of their role in chronic inflammatory dermatoses and potential as therapeutic targets', British Journal of Dermatology, 189, pp. 656 - 663, http://dx.doi.org/10.1093/bjd/ljad303
,2023, 'Human dermal fibroblast subpopulations and epithelial mesenchymal transition signals in hidradenitis suppurativa tunnels are normalized by spleen tyrosine kinase antagonism in vivo', Plos One, 18, pp. e0282763, http://dx.doi.org/10.1371/journal.pone.0282763
,2023, 'A proof-of-concept open-label clinical trial of spleen tyrosine kinase antagonism using fostamatinib in moderate-to-severe hidradenitis suppurativa', Journal of the American Academy of Dermatology, 89, pp. 694 - 702, http://dx.doi.org/10.1016/j.jaad.2023.05.076
,2023, 'Efficacy of topical diphencyprone for melanoma in-transit metastases: a systematic review and meta-analysis', Melanoma Research, 33, pp. 434 - 436, http://dx.doi.org/10.1097/CMR.0000000000000914
,2023, 'Knowledge, attitudes, and perceptions of hidradenitis suppurativa among young adults in Singapore', Jaad International, 12, pp. 72 - 80, http://dx.doi.org/10.1016/j.jdin.2023.03.010
,2023, 'Obesity and hidradenitis suppurativa: targeting meta-inflammation for therapeutic gain', Clinical and Experimental Dermatology, 48, pp. 984 - 990, http://dx.doi.org/10.1093/ced/llad182
,2023, 'Reply to Tilotta and Bongiorno: Considering the role of resident cutaneous memory T-cell suppression in providing durable atopic dermatitis remission', Journal of the European Academy of Dermatology and Venereology, 37, pp. e1173 - e1174, http://dx.doi.org/10.1111/jdv.19179
,2023, 'The impact of psoriasis biologic therapy on HIV viral load and CD4+ cell counts in HIV-positive individuals: A real-world cohort study', Journal of the European Academy of Dermatology and Venereology, 37, pp. 1659 - 1663, http://dx.doi.org/10.1111/jdv.19020
,2023, 'Treatment of alopecia areata with the janus kinase inhibitor upadacitinib: A retrospective cohort study', Journal of the American Academy of Dermatology, 89, pp. 137 - 138, http://dx.doi.org/10.1016/j.jaad.2022.12.056
,2023, 'Baseline clinical, hormonal and molecular markers associated with clinical response to IL-23 antagonism in hidradenitis suppurativa: A prospective cohort study', Experimental Dermatology, 32, pp. 869 - 877, http://dx.doi.org/10.1111/exd.14789
,2023, 'Maintenance of response to dupilumab in prurigo nodularis: A retrospective cohort study', Jaad International, 11, pp. 143 - 144, http://dx.doi.org/10.1016/j.jdin.2023.02.006
,2023, 'Academic dermatology in Australia and New Zealand between 2017 and 2022: A cross-sectional bibliometric analysis', Australasian Journal of Dermatology, 64, pp. 213 - 220, http://dx.doi.org/10.1111/ajd.14025
,2023, 'In search of therapeutic biomarkers to interleukin-23 antagonism in hidradenitis suppurativa', British Journal of Dermatology, 188, pp. 588 - 589, http://dx.doi.org/10.1093/bjd/ljad027
,2023, 'Angiotensin-converting enzyme 2 expression is elevated in tissue of hidradenitis suppurativa and pyoderma gangrenousm and demonstrates a different pattern of expression to psoriasis vulgaris', Journal of the European Academy of Dermatology and Venereology, 37, pp. e372 - e374, http://dx.doi.org/10.1111/jdv.18543
,2023, 'Monkeypox: Cutaneous clues to clinical diagnosis', Journal of the American Academy of Dermatology, 88, pp. 698 - 700, http://dx.doi.org/10.1016/j.jaad.2022.08.048
,2023, 'Strongyloides screening prior to dupilumab therapy in atopic dermatitis: a retrospective cohort study evaluating screening utility', British Journal of Dermatology, 188, pp. 294 - 295, http://dx.doi.org/10.1093/bjd/ljac060
,2023, 'A Randomized, Double-Blind, Biomarker-Selected, Phase II Clinical Trial of Maintenance Poly ADP-Ribose Polymerase Inhibition With Rucaparib Following Chemotherapy for Metastatic Urothelial Carcinoma', JOURNAL OF CLINICAL ONCOLOGY, 41, pp. 54 - +, http://dx.doi.org/10.1200/JCO.22.00405
,2023, 'Dupilumab-associated head and neck dermatitis resolves temporarily with itraconazole therapy and rapidly with transition to upadacitinib, with Malassezia-specific immunoglobulin E levels mirroring clinical response', Journal of the American Academy of Dermatology, 88, pp. 255 - 257, http://dx.doi.org/10.1016/j.jaad.2022.05.021
,2023, '1323 Human dermal fibroblasts and mast cell populations are altered in hidradenitis suppurativa, with epithelial-mesenchymal-transition signals ameliorated by spleen tyrosine kinase antagonism.', Journal of Investigative Dermatology, 143, pp. S227 - S227, http://dx.doi.org/10.1016/j.jid.2023.03.1339
,2023, 'LB1700 SYK antagonism in hidradenitis suppurativa demonstrates clinical efficacy with grearter response in B-cell predominant disease: Results of a open-label, proof-of-concept phase 2 clinical trial', Journal of Investigative Dermatology, 143, pp. B15 - B15, http://dx.doi.org/10.1016/j.jid.2023.06.074
,2022, 'Adalimumab therapy is associated with increased faecal short chain fatty acids in hidradenitis suppurativa', Experimental Dermatology, 31, pp. 1872 - 1880, http://dx.doi.org/10.1111/exd.14665
,2022, 'Real-world safety and clinical response of Janus kinase inhibitor upadacitinib in the treatment of hidradenitis suppurativa: A retrospective cohort study', Journal of the American Academy of Dermatology, 87, pp. 1440 - 1442, http://dx.doi.org/10.1016/j.jaad.2022.07.047
,2022, 'Metabolic syndrome and hidradenitis suppurativa: epidemiological, molecular, and therapeutic aspects', International Journal of Dermatology, 61, pp. 1175 - 1186, http://dx.doi.org/10.1111/ijd.15910
,2022, 'The road to biologics in patients with hidradenitis suppurativa: a nationwide drug utilization study*', British Journal of Dermatology, 187, pp. 523 - 530, http://dx.doi.org/10.1111/bjd.21673
,2022, 'Can we increase the drug survival time of biologic therapies in hidradenitis suppurativa?', Clinical and Experimental Dermatology, 47, pp. 1585 - 1586, http://dx.doi.org/10.1111/ced.15232
,2022, 'Interleukin-17RA blockade by brodalumab decreases inflammatory pathways in hidradenitis suppurativa skin and serum', British Journal of Dermatology, 187, pp. 223 - 233, http://dx.doi.org/10.1111/bjd.21060
,2022, 'Amplicon sequencing demonstrates comparable follicular mycobiomes in patients with hidradenitis suppurativa compared with healthy controls', Journal of the European Academy of Dermatology and Venereology, 36, pp. e580 - e583, http://dx.doi.org/10.1111/jdv.18075
,2022, 'Guidance on COVID-19 Vaccination in Hidradenitis Suppurativa Patients: A Modified Delphi Consensus of Experts', Skin Appendage Disorders, 8, pp. 287 - 290, http://dx.doi.org/10.1159/000521268
,2022, 'A case series of early biologic therapy in guttate psoriasis: Targeting resident memory T cell activity as a potential novel therapeutic modality', Jaad Case Reports, 24, pp. 82 - 87, http://dx.doi.org/10.1016/j.jdcr.2022.04.019
,2022, 'Dupilumab-associated head and neck dermatitis is associated with elevated pretreatment serum Malassezia-specific IgE: a multicentre, prospective cohort study', British Journal of Dermatology, 186, pp. 1050 - 1052, http://dx.doi.org/10.1111/bjd.21019
,2022, 'Extramammary Paget's disease Harbinger of internal malignancy', Australian Journal of General Practice, 51, pp. 351 - 352, http://dx.doi.org/10.31128/AJGP-05-21-5981
,2022, 'Large-scale serum analysis identifies unique systemic biomarkers in psoriasis and hidradenitis suppurativa*', British Journal of Dermatology, 186, pp. 684 - 693, http://dx.doi.org/10.1111/bjd.20642
,2022, 'Pyoderma gangrenosum: A systematic review of the molecular characteristics of disease', Experimental Dermatology, 31, pp. 498 - 515, http://dx.doi.org/10.1111/exd.14534
,2022, 'Autoantibody-Mediated Macrophage Responses Provide the Missing Link between Innate and Adaptive Immune Dysfunction in Hidradenitis Suppurativa', Journal of Investigative Dermatology, 142, pp. 747 - 749, http://dx.doi.org/10.1016/j.jid.2021.08.400
,2022, 'Dermatology and wound research: Targeting inflammation through cooperation and collaboration', Wound Practice and Research, 30, pp. 5, http://dx.doi.org/10.33235/wpr.30.1.5
,2022, 'Identification of Biomarkers and Critical Evaluation of Biomarker Validation in Hidradenitis Suppurativa: A Systematic Review', JAMA Dermatology, 158, pp. 300 - 313, http://dx.doi.org/10.1001/jamadermatol.2021.4926
,2022, 'Antimicrobial peptides in hidradenitis suppurativa: a systematic review*', British Journal of Dermatology, 186, pp. 236 - 244, http://dx.doi.org/10.1111/bjd.20750
,2022, 'The inflammatory proteome of hidradenitis suppurativa skin is more expansive than that of psoriasis vulgaris', Journal of the American Academy of Dermatology, 86, pp. 322 - 330, http://dx.doi.org/10.1016/j.jaad.2021.07.035
,2022, 'Biologic therapy is not associated with increased COVID-19 severity in patients with hidradenitis suppurativa: Initial findings from the Global Hidradenitis Suppurativa COVID-19 Registry', Journal of the American Academy of Dermatology, 86, pp. 249 - 252, http://dx.doi.org/10.1016/j.jaad.2021.09.016
,2022, 'Cutaneous infection and atopic dermatitis: the importance of early intervention in Indigenous children in Australia', Wound Practice and Research, 30, pp. 34 - 39, http://dx.doi.org/10.33235/wpr.30.1.34-39
,2022, 'High inflammation in hidradenitis suppurativa extends to perilesional skin and can be subdivided by lipocalin-2 expression', Journal of Allergy and Clinical Immunology, 149, pp. 135 - 144.e12, http://dx.doi.org/10.1016/j.jaci.2021.05.027
,2022, 'Pathergy: a review of potential mechanisms and novel therapeutic targets', Wound Practice and Research, 30, pp. 55 - 61, http://dx.doi.org/10.33235/wpr.30.1.55-61
,2022, 'Pyoderma gangrenosum: a review of the clinical, mechanistic and therapeutic landscape', Wound Practice and Research, 30, pp. 16 - 23, http://dx.doi.org/10.33235/wpr.30.1.16-23
,2022, 'Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial', LANCET ONCOLOGY, 23, pp. 1308 - 1320, http://dx.doi.org/10.1016/S1470-2045(22)00517-4
,2022, 'The pathogenesis of hidradenitis suppurativa: Evolving paradigms in a complex disease', Dermatological Reviews, 3, pp. 39 - 49, http://dx.doi.org/10.1002/der2.113
,2021, 'Assessing the responsiveness of sonographic biomarkers to Brodalumab therapy in Hidradenitis Suppurativa', Journal of the European Academy of Dermatology and Venereology, 35, pp. e884 - e887, http://dx.doi.org/10.1111/jdv.17536
,2021, 'Cellular neurothekeoma', International Journal of Women S Dermatology, 7, pp. 835 - 837, http://dx.doi.org/10.1016/j.ijwd.2021.07.011
,2021, 'Clinical considerations in the management of hidradenitis suppurativa in women[Formula presented]', International Journal of Women S Dermatology, 7, pp. 664 - 671, http://dx.doi.org/10.1016/j.ijwd.2021.10.012
,2021, 'A systematic review and critical appraisal of metagenomic and culture studies in hidradenitis suppurativa', Experimental Dermatology, 30, pp. 1388 - 1397, http://dx.doi.org/10.1111/exd.14141
,